

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



March 30, 2026

Company name:	Mochida Pharmaceutical Co., Ltd.
Name of representative:	Naoyuki Mochida, Representative Director, President
(Securities code:	4534 Prime Market, TSE)
Inquiries:	Kenichi Miyamoto, Head of Finance & Accounting Department
(Telephone:	+81-3-3358-7211)

**Notice Regarding Resolution on Share Repurchase**  
**(Share Repurchase under the provisions of the Articles of Incorporation pursuant to Article**  
**165, Paragraph 2 of the Companies Act)**

Mochida Pharmaceutical Co., Ltd. (the “Company”) hereby announces that a resolution was adopted by the Board of Directors held on March 30, 2026, in relation to the share repurchase in accordance with Article 156 of the Companies Act applied by replacing terms under the provisions of Article 165, Paragraph 3 of the Act as described below.

**Details of Repurchase**

- |     |  |   |
|-----|--|---|
| (1) | Class of shares to be repurchased:                   | Common stock of the Company   |
| (2) | Total number of shares authorized to be repurchased: | 530,000 shares (maximum)<br>(1.50% of total outstanding shares (excluding treasury shares)) |
| (3) | Total amount of the repurchase:                      | 2,000,000,000 yen (maximum)   |
| (4) | Repurchase period:                                   | From Monday, May 18, 2026 to Friday, December 18, 2026                                      |
| (5) | Repurchase Method:                                   | Market purchases on the Tokyo Stock Exchange, Inc.  |

(Note) Due to market trends and other factors, part of or all the shares may not be repurchased.

Reference: Status of treasury shares as of February 28, 2026

Total outstanding shares (excluding treasury shares):	35,449,727 shares
Number of treasury shares:	940,273 shares

**Disclaimer:** This document does not constitute an investment solicitation for any securities for sale. This document does not constitute an offer of investment in nor solicitation for purchase securities within the United States or elsewhere. The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933 or any relevant securities law of any state. The securities may not be offered or sold in the United States absent registration or an exemption from registration requirements under the U.S. Securities Act of 1933. No offers of securities for sale in the United States will be made in connection with the above-mentioned transactions.